IndustryCompany release

Phibro Animal Health lifts first-quarter sales 6% to $386.8m and keeps fiscal 2027 outlook

🇺🇸 Phibro Animal Health Corp (PAHC) · Wed 04 Nov 2026

The animal health and nutrition company reports an 11% rise in net income to $29.5m, with its guidance still assuming no virginiamycin sales in Brazil.

Phibro Animal Health (Nasdaq: PAHC) reported results for the quarter ended 30 September 2026 on 4 November 2026. Net sales rose 6% to $386.8 million, while net income increased 11% to $29.5 million.

The company said growth was led by its Mineral Nutrition and Performance Products businesses. No further segment figures were available in the material reviewed.

Phibro maintained its fiscal 2027 outlook. That guidance assumes there will be no further sales of virginiamycin in Brazil while the company seeks regulatory approval there for therapeutic claims for the product.

Virginiamycin is an antibiotic used in animal production. As general context, claims made on a veterinary medicinal product's label usually need to be supported by regulatory authorisation in the market concerned. The source material gave no timeline for the Brazilian approval process.

What it means for your team

  • Regulatory teams should note that Phibro ties its Brazil virginiamycin outlook to approval of therapeutic claims, not to a change in commercial demand.
  • Market-access teams in animal health should treat the guidance as assuming zero Brazilian virginiamycin sales until that approval is secured.
  • No approval date or regulatory milestone was disclosed in the available information, so timing remains open.

Company's press release (SEC filing): Phibro Animal Health Corp ↗

Article written by VigiEye from the official source (Phibro Animal Health Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →